Electronic Supplementary Material: Online Resource 4

International Journal of Clinical Oncology


Real-world analysis of treatment sequencing and late-stage liquid biopsy genomic profiling in advanced pancreatic cancer


Naohiro Nishida, Eisuke Iwasaki, Ken-Ichi Okada

Corresponding author: Naohiro Nishida
Department of Clinical Oncology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan
E-mail: nnishida@tokai.ac.jp


Online Resource 4. Kaplan–Meier curves comparing clinical outcomes between GnP and FFX as first-line therapy. Blue lines indicate GnP, and red lines indicate FFX.


a Patients harboring CHEK2 mutations: TTF (left) and OS (right).





b Patients harboring RAD51C mutations: TTF (left) and OS (right).





c Patients harboring BRIP1 mutations: TTF (left) and OS (right).

